Global Cancer Tumor (Organoids) "Modeling", Technology - & Personalized Cancer Research Insight 2025

Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025
Published
Number of pages
250

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
3300
3000
CD-ROM Mail Delivery
4200
4000
Hard Copy Mail Delivery
5100
5000
Electronic Access - Multi-User License
6000
5500

"Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025" Report Highlights:

  • Application of Organoids by Cancer Therapeutic

  • CRISPR-Cas9 Potential Applications in Cancer Organoids

  • Cancer Organoid Market Opportunity Assessment: >US$ 400 Million

  • Clinical Trials Registered under Cancer Organoids

  • Personalized Cancer Therapy Using Cancer Organoids

  • Joint Ventures to Accelerate Drug Discovery through Organoids

The development of cancer organoids has transformed the widespread adoption of the traditional 2D cell lines in the research community. The technology of cancer organoids holds a significant potential to study variety of areas such as cancer disease pathology, cancer biology, precision medicine, drug development, drug testing and drug efficacy testing. For the mentioned areas, cancer organoid technology constitutes tremendous informative complimentary approaches to the already available two-dimensional culture method and animal model system.

"Report Highlights The Ongoing Clinical Advancement In Cancer Organoids & Helps To Identify The Application Of Organoids Platform Across Multiple Cancers In Order To Develop More Personalized Cancer Therapy & Drug Screening"

On an average, the development of organoid culture represents a novel technology for studying human disease and human development. The ability of the organoids to resemble the original human tissue, form the correct type of cell and to perform the specific functions of the tissues helps in gaining the confidence of working on human cancer organoids and for the development of treatments against human cancers. Cancer organoids faithfully recapitulate the different aspects of tissue composition, function and architecture ex vivo and by doing so they set a great example of an advanced technology that comes with the possibility of opening up and identifying novel therapeutics strategies in personalizing the human disease model.

"The Organoid Technology Has The Advantage Of Predicting The Accurate Response Than Any Other 2D Cell Culture Models Available. It Carries Better Capacity To Unravel The Heterogeneity Within Individual Patients And Is Combined With High Throughput Screening Technology Than The Xenografts Model"

All this advancement should enable the cancer organoid technology to develop its place at the top and marking itself as an important tool in predicting the response of the cancer patients towards cancer treatment in the future. Till now, majority of the cancer organoids have been generated for adenocarcinomas and very less organoids are currently available for the squamous cell carcinomas. Since the development of cancer organoids from the cancer tumors in vivo, it has opened up new avenues for the investigation and identification of new drugs and treatments. As organoids can be developed from various types of cancer, therefore it offers a great potential towards investigating treatment responses in the patient personally and therefore is expected to provide a better insight into the precision medicine in the future.

For the future research, organoid technology is expected to present a crucial position and it is undoubtedly successful in revolutionizing the technical, preclinical and clinical techniques adapted in the laboratories. The technology of developing a complete organ in vitro from small amount of cells is considered as groundbreaking as the discovery of antibiotics, vaccines and chemotherapy in the fight against different human diseases. The technology requires few years and some advancement, to be dominant over the other available technologies.

1. Introduction to Organoids

  1.1 Organoids

  1.2 History of the Development

  1.3 Timeline for Patient Derived Tumor Organoid (PDTO) Development

 

2. Cancer Organoids: Promising Tool for Cancer Biologists

   2.1 Cancer Organoids Revealing the Cancer Dynamics

  2.2 Cancer Organoids: An Intermediate Platform for Targeted Therapy

 

3. Human Cancer Modeling

  3.1 Growth Factors & Small Molecule Inhibitors Applied In Organoid Cultures

  3.2 Culture Systems of Multiple Tumoroids

  3.3 Human Organoid Protocol

  3.4 Extraction Methods for Initiating an Organoid Generation

    3.4.1 Biopsy

    3.4.2 Surgery

 

4. Establishment of Cancer Organoids

  4.1 In-vitro Establishment of Stomach Cancer Organoid Cancer

  4.2 Invasion of In-Vivo Mutations in In-Vitro Organoid Model of Intestinal Cancer

  4.3 Expansion of Liver Cancer Organoids in the Laboratories

  4.4 In- Vitro Modeling of Pancreatic Cancer Organoid

  4.5 Transformation of Breast Cancer Cells into Organoids

  4.6 3D Organoid Model Generation for Bladder Cancer

  4.7 Obtaining In-Vitro Model of In-Vivo Prostate Cancer

  4.8 Miniature Organ Development from the In-Vivo Ovarian Cancer Cells

  4.9 Creation of In-Vivo Esophageal Cancer as an In-Vitro Organoid Model

 

 

5. Cancer Organoids & Other Laboratory Techniques to Assess Treatment Responses

  5.1 Cell Lines

  5.2 Patient-Derived Xenografts

  5.3 Organotypic Tissue Slice Culture

  5.4 Cancer Organoids: Marking a New Territory

 

6. Tumors Organoids Accelerating Cancer Treatment

  6.1 Cancer Epidemic & Pre-Screening

  6.2 Cancer Organoids Predicting Tumor Responses

 

7. Advantages of Cancer Organoids

  7.1 Reduction in Experimental Complexity Through Cancer Organoids Models

  7.2 Similar Genetic Representation between the Organoid & Parent Tumor Organ

  7.3 Cancer Organoid Models Predicting the Response of Cancer Treatment

  7.4 Cancer Organoid Models Retaining the Phenotype of Parent Organ after Development

  7.5 Cancer Organoid Models Supporting Biomarker Profiling in Cancer Research

 

8. Cancer Organoids: Advanced Research & Therapeutic Potential

  8.1 Cancer Organoids: Revolutionizing Novel Anti-Cancer Drug Testing Methodology

  8.2 Mini-Organ Toxicity Demonstration by Cancer Organoids

  8.3 Pharmacokinetics & Pharmacodynamics Analysis Enabled by Cancer Organoids

  8.4 Cancer Organoids: Innovations in Drug Development Method

  8.5 Cancer Organoids as a Potential Platform for Personalized Cancer Therapy

 

9. Organoid Development Transforming Basic Medical Research

  9.1 Organoids Advancement in Organ Replacement

  9.2 Analyzing Gene Therapy on Organoids

  9.3 Organoids for Cell Therapy Analysis

 

 

10. Post-Model Generation Screening of Cancer Organoids

  10.1 Identical Genetic Characteristics between Cancer Organoid & Parent Organ

  10.2 Maintaining the Histology of Cancer Organ Tissues

  10.3 Tumorigenic Characteristic Screening of Cancer Organoids

 

11. Patient-Derived Tumor Organoids & its Achievement in Medical Research

  11.1 Translational Application of Cancer organoid Models

  11.2 Cancer Organoids Promoting Oncogenic Mutation Study

  11.3 Integration of the Microenvironment Induced by Cancer Organoids

 

12. CRISPR-Cas9 Potential Applications in Cancer Organoids

  12.1 CRISPR-Cas9: A Promising Gene Editing Technology

  12.2 CRISPR-Cas9 Mediated Cancer Organoid Technology

  12.3 CRISPR Based Gene Edited Organoids Recapitulating Cancer Mutations

 

13. Organoids for the Study of Pancreatic Cancer

  13.1 Human Endocrine & Exocrine Cancer Pancreatic 3D Model to Transform Cancer Treatment

  13.2 Development of Pancreas 3D Cancer Organoid System

  13.3 Applications of 3D Pancreatic Organoid Culture

     13.3.1 Pancreatic Cancer Organoid & Genetic Implementation

     13.3.2 Pancreatic Cancer Organoid & the Inner Environment Benefits

     13.3.3 Pancreatic Cancer Organoid Model for Drug Toxicity Screening

     13.3.4 Pancreatic Cancer Organoid Provoking Personalized Therapy

 

14. Organoids for the Study of Stomach Cancer

  14.1 Development of Stomach Cancer Organoid Culture

  14.2 High-Throughput Screening with Stomach Cancer Organoid 3D Model

     14.2.1 Tumorigenesis with Stomach Cancer Organoids

     14.2.2 Stomach Cancer Organoids Screening Drug Sensitivity

     14.2.3 Developing Stomach Cancer Biobanks for Drug Screening

   14.2.4 Stomach Cancer Organoids for Personalizing Therapy

 

15. Three-Dimensional Culture of Liver Organoid in Cancer Biology

  15.1 Development of Liver Organoids

  15.2 Progress & Potential of Organoid Towards Liver Cancer

    15.2.1 Liver Cancer Organoids as a New Model for Improving Drug Screening

    15.2.2 Primary Liver Cancer Organoids for Novel Drug Discovery

    15.2.3 Primary Liver Cancer Organoids Creating the Living Biobank for the Future Therapeutic Challenges

    15.2.4 Primary Liver Cancer Organoids Transforming Personalized Therapy

 

16. Advanced Development of Breast Cancer Organoids

  16.1 Organoid Technology to Transform Breast Cancer Modeling & Development

  16.2 An Organoid Approach Marking Breast Cancer Therapeutic Research

    16.2.1 Breast Cancer Organoids in Drug Development & Expansion

    16.2.2 Breast Cancer Organoids: An in-vitro Model for Cancer Biomarker Discovery

    16.2.3 Breast Cancer Organoids as a Powerful Resource for Personalized Therapy

 

17. Kidney Cancer Organoids for Cancer Research & Therapeutic Challenges

  17.1 Kidney Cancer Organoids: Developmental Approach & Characteristics Analysis

  17.2 Organoid Technology & its Applications in Treating Kidney Cancer

    17.2.1 Kidney Cancer Organoids Actively Participating in the Pre-Clinical & Clinical Trials

    17.2.2 Validation of Cancer Biomarkers by Kidney Cancer Organoids in Drug Development

 

18. Organoids for the Development of Lung Cancer

  18.1 Generation of Lung Cancer Organoid from Lungs Tissue

  18.2 Lung Cancer Organoids: A Novel 3D Platform for Therapeutic Research

   18.2.1 Lung Cancer Organoids for Therapeutic Screening & Cancer Research

   18.2.2 Organoids Re-Creating the Treatment for Lung Cancer

 

 

19. Ovarian Cancer Organoids & its role in Therapeutic Advancement

  19.1 Organoid Model Recapitulating Human Ovarian Cancer

  19.2 Validation of Potential Benefits Received from Patient-Derived Ovarian Cancer Organoid Model

    19.2.1 Editing of Oncogenes in the Patient Derived Ovarian Cancer Organoids

    19.2.2 Screening & Drug Testing on Human Ovarian Cancer Organoid Model

    19.2.3 Ovarian Cancer Organoids in Modeling the Ovarian Cancer Development & Progression

 

20. An Organoid Platform for Oncological Research in Bladder Cancer

  20.1 Establishment of High-Resolution 3D Organoid Model for Bladder Cancer

  20.2 Efficient Use of 3D Bladder Cancer Organoids in Oncology Landscape

    20.2.1 3D Bladder Cancer Organoids at an Uprising Scale for Drug Discovery

    20.2.2 Testing & Screening of Drugs using Bladder Cancer Organoids

    20.2.3 Patient-Derived Bladder Cancer Organoids Predicting Response to Various Cancer Treatments

 

21. Human Primary Head & Neck Cancer: An Organoid Approach for In-depth Clinical Research

  21.1 Generation & Culture of 3D Head & Neck Cancer Organoids

  21.2 Patient-Derived Head & Neck Cancer Organoids Re-defining the Cancer Research

    21.2.1 Broad Activity of Head & Neck Cancer Organoids towards Cancer Modeling

    21.2.2 Transformation of Drug Development & Drug Efficacy Strategies in Head & Neck Cancer using Organoid Technology

 

22. Living Biobanks of Cancer Organoids Representing Histopathological Diversity

  22.1 The Potential of Living Biobank towards Precision Medicine

  22.2 Living Bio-banking Strategy Offering Novel Therapeutics for Basic & Advanced Cancer Research

 

23. Drivers & Challenges Associated with Cancer Organoids

  23.1 Drivers Witnessing the Growth of Cancer Organoid Technology

  23.2 Challenges Concerning the Growth of Cancer Organoids

 

24. Future Directions of Organoids in Cancer Research

 

25. Strategic Joint Ventures by Pharma Companies to Accelerate Drug Discovery through Organoids

  25.1 Expanded Breast Cancer Organoids License Agreement between Cellesce & Hubrecht Organoid Technology

  25.2 Pre-Clinical Anti-Cancer Drug Development between HUB Organoid Technology & Crown Biosciences

  25.3 SEngine’s & Atomwise’s New Joint Venture to Boost Drug Discovery through Organoids

 

26. Clinical Trials Registered under Cancer Organoids

  26.1 Lung Cancer

    26.1.1 Clinical Trial - Patient-Derived Organoids of Lung Cancer to Test Drug Responses

    26.1.2 Clinical Trial - Patient-Derived Organoid Model & Circulating Tumor Cell for Treatment Responses of Lung Cancer

    26.1.3 Clinical Trial - Drug Sensitivity Correlation between Patient-Derived Organoid Model & Clinical Responses in Non-Small Cell Lung Cancer Patients

  26.2 Breast Cancer

   26.2.1 Clinical Trial – Clinical Study on Drug Sensitivity Verification or Prediction for Breast Cancer by Patient-Derived Organoid Model

  26.3 Pancreatic Cancer

    26.3.1 Clinical Trial – Drug Screening of Pancreatic Cancer Organoids Developed from EUS-FNA Guided Biopsy Tissues

  26.4 Esophageal Cancer

    26.4.1 Clinical Trial - Chemoradioresistnace in Prospectively Isolated Cancer Stem Cells in Esophageal Cancer – Organoid: RARE STEM Organoid

 

27. Current Market Scenario of Cancer Organoid Technology

  27.1 Market Trends

  27.2 Market Overview

    27.2.1 North America

    27.2.2 Europe

   27.2.3 Asia-Pacific

 

28. Competitive Landscape

  28.1 Cellesce

  28.2 MIMETAS

   28.3 Hubrecht Organoid Technology

   28.4 Crown Biosciences

  28.5 Atomwise

   28.6 STEMCELL Technologies

  28.7 Qgel

  28.8 OcellO

  28.9 DefiniGEN

Figure 1-1: Organoid Culture Establishment

Figure 1-2: Timeline for PDTO Development

 

Figure 2-1: Strategy of Cancer Organoids

Figure 2-2: Cancer Organoid Establishment

Figure 2-3: Organoids Leading to Mutational Analysis of Cancer

Figure 2-4: Cancer Organoid as a Targeted Therapy

 

Figure 3-1: Human Organoid Development Protocol

Figure 3-2: Sample Collection through Biopsy

Figure 3-3: Sample Collection through Surgery

 

Figure 4-1: Developed Cancer Organoids

 

Figure 5-1: Available Methods for Cancer Assessment

Figure 5-2: Diagrammatic Representation of Currently Available Techniques

Figure 5-3: Establishment of Cultures through Cell Lines

Figure 5-4: Establishment of Patient-Derived Xenograft Models

Figure 5-5: Disadvantages of Patient-Derived Xenografts

Figure 5-6: Organotypic Tissue Slice Culture Preparation

Figure 5-7: Cancer Organoids Dominating Other Techniques

Figure 5-8: Characteristics of Cancer Organoid Model System

 

Figure 6-1: Pre-Screening Test Leading to Accelerated Cancer Treatment

 

Figure 7-1: Advantages of Cancer Organoids

Figure 7-2: Cancer Organoids Preserving Genetic Information

Figure 7-3: Cancer Organoids Predicting Cancer Treatment

Figure 7-4: Benefits of Preserving Phenotypic Characteristics by Cancer Organoids

Figure 7-5: Organoids & Human Organ Showing Similar Results

Figure 7-6: Biomarkers Application in the Medical World

Figure 7-7: Biomarkers Predicting Cancer Treatment Response

 

Figure 8-1: Applications of Cancer Organoids in Research

Figure 8-2: Difference Between 2D Screening & 3D Screening of Drugs

Figure 8-3: Cancer Organoids During the Detection of Drug Toxicity

Figure 8-4: Relationship between Pharmacokinetics & Pharmacodynamics

Figure 8-5: Benefits of Pharmacodynamics & Pharmacokinetics Analysis

Figure 8-6: Drug Discovery Cycle

Figure 8-7: Cancer Organoids during Drug Development

Figure 8-8: Personalized Cancer Therapy

Figure 8-9: Scientific Advances Leading to Personalized Therapy

Figure 8-10: Benefits of Personalized Therapy for the Patients

Figure 8-11: Personalized Cancer Therapy Using Cancer Organoids

 

Figure 9-1: Application of Organoids in Basic Medical Research

Figure 9-2: Process of Organ Donation

 

Figure 10-1: Post-Model Generation Screening Characteristics

Figure 10-2: Genetic Analysis of the Developed Organoid

Figure 10-3:  Histological Maintenance of the Tumor Organoids

Figure 10-4: Characteristics of Tumor

 

Figure 11-1: Patient-Derived Tumor Organoids Progress Fields

 

Figure 12-1: Potential Applications of CRISPR-Cas9

Figure 12-2: Establishment of ESC or iPSC & ASC Derived Organoids

Figure 12-3: Applications of CRISPR Based Gene Edited Organoids

 

Figure 13-1: Generation & Applications of Pancreatic Cancer Organoid

Figure 13-2: Potential Applications of Organoid Derived from Pancreatic Cancer Cells

Figure 13-3: Personalized Therapy - Essential Requirements

 

Figure 14-1: Common Stomach Cancer Causing Agents

Figure 14-2: Human Stomach Cancer Organoid Culture

Figure 14-3: Applications of Stomach Cancer Organoids

 

 

Figure 15-1: Primary Liver Cancer Causing Diseases

Figure 15-2: Liver Organoids Derived from Tissue-Resident Stage & Embryonic Stage

Figure 15-3: Liver Organoids Derived from Induced Pluripotent Stem Cells

Figure 15-4: Post-Model Screening of Liver Organoid

Figure 15-5: Potential Applications of Primary Liver Cancer Organoids

Figure 15-6: Essential Requirements for Developing Personalized Vaccine

 

Figure 16-1: Risk Factors for Breast Cancer

Figure 16-2: Development of Breast Organoids

Figure 16-3: Applications of Breast Cancer Organoids in Breast Cancer Research

Figure 16-4: Steps for the Development of a Drug

Figure 16-5: Applications of Cancer Biomarkers

 

Figure 17-1: Risk Factors Associated with Renal Cell Carcinoma

Figure 17-2: Development of Kidney Cancer Organoids

Figure 17-3: Essential Requirements for Developing Kidney Cancer Organoids

Figure 17-4: Potential Applications of Kidney Cancer Organoids

Figure 17-5: Kidney Cancer Organoids for Studying Gene-Drug Association

Figure 17-6: Key Features of Cancer Biomarkers

 

Figure 18-1: Risk Factors Associated with Lung Cancer

Figure 18-2: Establishment of Lung Cancer Organoids

Figure 18-3: Characteristic Analysis for a Developed Organoid

Figure 18-4: Applications of Lung Cancer Organoids

Figure 18-5:  Lung Cancer Organoids Towards Therapeutic Research

 

Figure 19-1: Risk Factors Associated with Prevalence of Ovarian Cancer

Figure 19-2: Human Ovarian Cancer Organoid Development

Figure 19-3: Characteristics Analysis of the In Vitro Model

Figure 19-4: Benefits of Developing Human Ovarian Cancer Organoid Model

 

Figure 20-1: Risk Factors & Symptoms Associated with Bladder Cancer

Figure 20-2: Establishment of Bladder Cancer Organoid

Figure 20-3: Characteristics Analysis for Developed Bladder Cancer Organoid

Figure 20-4: Key Applications of Bladder Cancer Organoids in Cancer Research

Figure 20-5: Dimensions for Personalized Medicine

Figure 20-6: Personalized Therapy

 

Figure 21-1: Risk factors & Symptoms Linked with the Development of Head & Neck Cancer

Figure 21-2: Generation of 3D Head & Neck Cancer Organoid

Figure 21-3: Characteristic Analysis of Developed Head & Neck Cancer Organoid

Figure 21-4: Key Applications of Head & Neck Cancer Organoids

Figure 21-5: Head & Neck Cancer Organoids Challenging Drug Development Strategies

 

Figure 22-1: Process of Bio-banking

Figure 22-2: Living Biobank of Organoid Allowing Different Experiments at Same Type

 

Figure 23-1: Drivers of Cancer Organoids

 

Figure 24-1: Future of Cancer Organoids

 

Figure 26-1: Start & Estimated Completion Date of the Clinical Trial

Figure 26-2: Start & Estimated Completion Date of the Clinical Trial

Figure 26-3: Start & Estimated Completion Date of the Clinical Trial

Figure 26-4: Start & Estimated Completion Date of the Clinical Trial

Figure 26-5: Start & Estimated Completion Date of the Clinical Trial

Figure 26-6: Start & Estimated Completion Date of the Clinical Trial

 

Figure 27-1: Market Share of Organoid by Applications

Figure 27-2: Global - Cancer Organoid Market Opportunity Assessment (US$ Million), 2020 -2025

Figure 27-3: Global - Percentage of New Cancer Cases, 2018

Figure 27-4: Global - Percentage of Cancer Deaths, 2018

Figure 27-5: United States – Companies Working on Organoid Technology

Figure 27-6: North America – Percentage of New Cancer Cases, 2018

Figure 27-7: North America – Percentage of New Cancer Cases in Males, 2018

Figure 27-8: North America – Percentage of New Cancer Cases in Females, 2018

Figure 27-9: USA - Percentage of New Cancer Cases, 2018

Figure 27-10: USA - Percentage of New Cancer Cases in Males, 2018

Figure 27-11: USA - Percentage of New Cancer Cases in Females, 2018

Figure 27-12: Canada - Percentage of New Cancer Cases, 2018

Figure 27-13: Canada - Percentage of New Cancer Cases in Males, 2018

Figure 27-14: Canada - Percentage of New Cancer Cases in Females, 2018

Figure 27-15: Mexico - Percentage of New Cancer Cases, 2018

Figure 27-16: Mexico - Percentage of New Cancer Cases in Males, 2018

Figure 27-17: Mexico - Percentage of New Cancer Cases in Females, 2018

Figure 27-18: US – Total Urothelial Cancer Drugs Market Size (US$ in Million), 2017 - 2018

Figure 27-19: Global Urothelial Cancer Drug Market Share, 2017

Figure 27-20: European Companies Working On Organoid Technology

Figure 27-21: Europe – Cancer Therapeutics Share by Type, 2018

Figure 27-22: Europe – Percentage of Cancer Cases, 2018

Figure 27-23: Europe – Percentage of Cancer Cases in Males, 2018

Figure 27-24: Europe – Percentage of Cancer Cases in Females, 2018

Figure 27-25: Germany - Percentage of Cancer Cases, 2018

Figure 27-26: Germany - Percentage of Cancer Cases in Males, 2018

Figure 27-27: Germany - Percentage of Cancer Cases in Females, 2018

Figure 27-28: United Kingdom – Percentage of Cancer Cases, 2018

Figure 27-29: United Kingdom – Percentage of Cancer Cases in Males, 2018

Figure 27-30: United Kingdom – Percentage of Cancer Cases in Females, 2018

Figure 27-31: France - Percentage of New Cancer Cases, 2018

Figure 27-32: France - Percentage of New Cancer Cases in Males, 2018

Figure 27-33: France – Percentage of New Cancer Cases in Females, 2018

Figure 27-34: Europe – Clinical Trial Market Value (US$ in Billion), 2018- 2024

Figure 27-35: Asia–Pacific – Clinical Trial Market Value (US$ in Billion), 2019 - 2024

Figure 27-36: Japan – Percentage of New Cancer Cases, 2018

Figure 27-37: Japan – Percentage of New Cancer Cases in Males, 2018

Figure 27-38: Japan – Percentage of New Cancer Cases in Females, 2018

Figure 27-39: China – Percentage of New Cancer Cases, 2018

Figure 27-40: China – Percentage of New Cancer Cases in Males, 2018

Figure 27-41: China – Percentage of New Cancer Cases in Females, 2018

Figure 27-42: India – Percentage of New Cancer Cases, 2018

Figure 27-43: India – Percentage of New Cancer Cases in Males, 2018

Figure 27-44: India – Percentage of New Cancer Cases in Females, 2018

Figure 27-45: South Korea – Percentage of New Cancer Cases, 2018

Figure 27-46: South Korea – Percentage of New Cancer Cases in Males, 2018

Figure 27-47: South Korea – Percentage of New Cancer Cases in Females, 2018

 

List of Tables

 

Table 3-1: Available Growth Factors & Molecule Inhibitors   

Table 3-2: Available Culture Systems for Different Tumoroids